PHIO PHARMACEUTICALS CORP. Research and Development Asset Acquired Other than Through Business Combination, Written-off
PHIO PHARMACEUTICALS CORP. (PHIO) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2019-03-27
- PHIO PHARMACEUTICALS CORP. research and development asset acquired other than through business combination, written-off for the quarter ending 2018-12-31 was $0.00.
- PHIO PHARMACEUTICALS CORP. research and development asset acquired other than through business combination, written-off for the quarter ending 2018-09-30 was $0.00.
- PHIO PHARMACEUTICALS CORP. research and development asset acquired other than through business combination, written-off for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. research and development asset acquired other than through business combination, written-off for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. research and development asset acquired other than through business combination, written-off for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- PHIO PHARMACEUTICALS CORP. research and development asset acquired other than through business combination, written-off for fiscal 2017 was $4.70M.
- PHIO PHARMACEUTICALS CORP. research and development asset acquired other than through business combination, written-off for fiscal 2015 was $228.00K.
- PHIO PHARMACEUTICALS CORP. research and development asset acquired other than through business combination, written-off for fiscal 2013 was $12.25M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-27 | $0.00 derived: sum of 2 quarters · filed 2019-03-27 | $0.00 derived: sum of 3 quarters · filed 2019-03-27 | $0.00 10-K · filed 2019-03-27 | |||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-14 | $0.00 10-Q · filed 2018-11-14 | $0.00 derived: sum of 4 quarters · filed 2019-03-27 | |||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-14 | $0.00 10-Q · filed 2018-08-14 | $0.00 derived: sum of 3 quarters · filed 2019-03-27 | $0.00 derived: sum of 4 quarters · filed 2019-03-27 | |||
| 2018-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2019-03-27 | $0.00 derived: sum of 2 quarters · filed 2019-03-27 | $0.00 derived: sum of 3 quarters · filed 2019-03-27 | $85.00K derived: sum of 4 quarters · filed 2019-03-27 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-27 | $0.00 derived: sum of 2 quarters · filed 2019-03-27 | $85.00K derived: sum of 3 quarters · filed 2019-03-27 | $4.70M 10-K · filed 2019-03-27 | |||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-14 | $85.00K derived: sum of 2 quarters · filed 2018-11-14 | $4.70M 10-Q · filed 2018-11-14 | $3.08M 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | $85.00K 10-Q · filed 2018-08-14 | $4.70M 10-Q · filed 2018-08-14 | $3.08M 10-Q · filed 2017-08-10 | ||||
| 2017-03-31 | $4.61M 10-Q · filed 2018-05-10 | $2.99M 10-Q · filed 2017-05-11 | |||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | $0.00 derived: sum of 2 quarters · filed 2017-03-30 | $0.00 derived: sum of 3 quarters · filed 2017-03-30 | $228.00K 10-K · filed 2017-03-30 | |||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $0.00 derived: sum of 2 quarters · filed 2016-11-10 | $228.00K 10-Q · filed 2016-11-10 | ||||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $228.00K 10-Q · filed 2016-08-11 | |||||
| 2015-03-31 | $228.00K 10-Q · filed 2016-05-12 | ||||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $0.00 derived: sum of 2 quarters · filed 2015-03-30 | $0.00 derived: sum of 3 quarters · filed 2015-03-30 | $12.25M 10-K · filed 2015-03-30 | |||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $0.00 derived: sum of 2 quarters · filed 2014-11-13 | $12.25M 10-Q · filed 2014-11-13 | ||||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $12.25M 10-Q · filed 2014-08-14 | |||||
| 2013-03-31 | $12.25M 10-Q · filed 2014-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |